Get the facts, then choose a treatment that fits your life.

^aFEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors.
^bIn patients with hemophilia A or B with inhibitors.
^cIndividual doses for a joint bleed are compared and based on an 88-kg (194-lb) person.
^dPatients are cautioned that the maximum injection or infusion rate must not exceed 2 units per kilogram of body weight per minute.
All information from FEIBA Package Insert.
^eRedosing time does not correlate to body weight.
^fMaximum daily dose.

^gPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance, may be eligible to receive a limited supply of free product. Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.